CA3053116A1 - Methods for the detection and treatment of lung cancer - Google Patents
Methods for the detection and treatment of lung cancer Download PDFInfo
- Publication number
- CA3053116A1 CA3053116A1 CA3053116A CA3053116A CA3053116A1 CA 3053116 A1 CA3053116 A1 CA 3053116A1 CA 3053116 A CA3053116 A CA 3053116A CA 3053116 A CA3053116 A CA 3053116A CA 3053116 A1 CA3053116 A1 CA 3053116A1
- Authority
- CA
- Canada
- Prior art keywords
- antigen
- lung cancer
- sftpb
- subject
- pro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6848—Methods of protein analysis involving mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
- G16B40/10—Signal processing, e.g. from mass spectrometry [MS] or from PCR
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16B5/00—ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B5/20—Probabilistic models
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Computational Biology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Spectroscopy & Molecular Physics (AREA)
- Biophysics (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Evolutionary Biology (AREA)
- Theoretical Computer Science (AREA)
- Physiology (AREA)
- Probability & Statistics with Applications (AREA)
- Databases & Information Systems (AREA)
- Evolutionary Computation (AREA)
- Bioethics (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Data Mining & Analysis (AREA)
- Signal Processing (AREA)
- Epidemiology (AREA)
- Artificial Intelligence (AREA)
- Public Health (AREA)
- Software Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762456731P | 2017-02-09 | 2017-02-09 | |
| US62/456,731 | 2017-02-09 | ||
| PCT/US2018/017704 WO2018148600A1 (en) | 2017-02-09 | 2018-02-09 | Methods for the detection and treatment of lung cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3053116A1 true CA3053116A1 (en) | 2018-08-16 |
Family
ID=63107741
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3053116A Pending CA3053116A1 (en) | 2017-02-09 | 2018-02-09 | Methods for the detection and treatment of lung cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US12504430B2 (https=) |
| EP (2) | EP4528741A3 (https=) |
| JP (1) | JP7311417B2 (https=) |
| KR (2) | KR102827354B1 (https=) |
| CN (2) | CN110291397A (https=) |
| CA (1) | CA3053116A1 (https=) |
| ES (1) | ES2995959T3 (https=) |
| WO (1) | WO2018148600A1 (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110291397A (zh) | 2017-02-09 | 2019-09-27 | 得克萨斯大学体系董事会 | 肺癌的检测和治疗方法 |
| WO2021016711A1 (en) * | 2019-07-29 | 2021-02-04 | Biomark Cancer Systems Inc. | Method of discriminating lung cancer patients |
| CA3165068A1 (en) | 2020-01-30 | 2021-08-05 | John E. Blume | Lung biomarkers and methods of use thereof |
| EP4143578B1 (en) * | 2020-04-28 | 2024-06-05 | Luxembourg Institute of Health (LIH) | Biomarkers for detection of lung cancer |
| WO2022051753A1 (en) * | 2020-09-01 | 2022-03-10 | Oncodea Corporation | Predictive diagnostic test for early detection and monitoring of diseases |
| CN112147099A (zh) * | 2020-09-22 | 2020-12-29 | 范庆坤 | 一种m蛋白紫外分光检测法 |
| KR20230080442A (ko) * | 2020-10-02 | 2023-06-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 폐암의 검출 및 치료를 위한 방법 |
| EP4237090B1 (en) * | 2020-10-29 | 2026-02-18 | Board of Regents, The University of Texas System | Methods for the detection and treatment of ovarian cancer |
| AU2021409465A1 (en) | 2020-12-21 | 2023-08-03 | Freenome Holdings, Inc. | Markers for the early detection of colon cell proliferative disorders |
| US12334190B2 (en) | 2021-03-31 | 2025-06-17 | PrognomIQ, Inc. | Multi-omic assessment using proteins and nucleic acids |
| GB2607436A (en) * | 2021-03-31 | 2022-12-07 | Prognomiq Inc | Multi-omic assessment |
| CN113267587B (zh) * | 2021-05-27 | 2023-11-10 | 杭州广科安德生物科技有限公司 | 测定pro-SFTPB标准物质含量的特征肽段及方法 |
| US12387508B2 (en) | 2021-09-10 | 2025-08-12 | PrognomIQ, Inc. | Direct classification of raw biomolecule measurement data |
| US12007397B2 (en) | 2021-09-13 | 2024-06-11 | PrognomIQ, Inc. | Enhanced detection and quantitation of biomolecules |
| WO2023209218A1 (en) * | 2022-04-28 | 2023-11-02 | Janssen Pharmaceutica Nv | Metabolite predictors for lung cancer |
| EP4357782A1 (en) * | 2022-10-18 | 2024-04-24 | MU Bioteknik Aktiebolag | Protein biomarker panel for the diagnosis of colorectal cancer |
| CN115575636B (zh) * | 2022-11-22 | 2023-04-04 | 杭州广科安德生物科技有限公司 | 一种用于肺癌检测的生物标志物及其系统 |
| CN116593702B (zh) * | 2023-05-11 | 2024-04-05 | 杭州广科安德生物科技有限公司 | 一种肺癌的生物标志物以及诊断系统 |
| WO2025064345A2 (en) * | 2023-09-22 | 2025-03-27 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of lung cancer |
| CN118983078B (zh) * | 2024-08-15 | 2025-03-25 | 立本医疗器械(成都)有限公司 | 基于ptr-tof-ms的肺癌筛查模型构建方法 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1969363B1 (en) * | 2005-12-22 | 2016-11-30 | Abbott Molecular Inc. | Methods and marker combinations for screening for predisposition to lung cancer |
| US9347945B2 (en) | 2005-12-22 | 2016-05-24 | Abbott Molecular Inc. | Methods and marker combinations for screening for predisposition to lung cancer |
| US20080133141A1 (en) * | 2005-12-22 | 2008-06-05 | Frost Stephen J | Weighted Scoring Methods and Use Thereof in Screening |
| CA2681667A1 (en) * | 2007-05-18 | 2008-11-27 | Duke University | Serum biomarkers for the early detection of lung cancer |
| WO2012006632A2 (en) | 2010-07-09 | 2012-01-12 | Somalogic, Inc. | Lung cancer biomarkers and uses thereof |
| EP2567232A1 (en) * | 2010-05-07 | 2013-03-13 | AbbVie Inc. | Methods for predicting sensitivity to treatment with a targeted tyrosine kinase inhibitor |
| US20120087860A1 (en) * | 2010-05-24 | 2012-04-12 | Marek Malecki | Methods for in vivo cancer detection, diagnosis and therapy using multidomain biotags |
| WO2011150974A1 (en) | 2010-06-03 | 2011-12-08 | Porto Conte Ricerche S.R.L. | Biomarkers for lung neuroendocrine tumors |
| CN102321760A (zh) * | 2011-08-26 | 2012-01-18 | 泸州医学院附属医院 | 一种非小细胞肺癌标志物及应用 |
| CA2799163C (en) * | 2011-12-18 | 2025-01-07 | 20/20 Genesystems, Inc. | Methods and algorithms for aiding in the detection of cancer |
| WO2013154998A1 (en) | 2012-04-09 | 2013-10-17 | Duke University | Serum biomarkers and pulmonary nodule size for the early detection of lung cancer |
| US20140271453A1 (en) * | 2013-03-14 | 2014-09-18 | Abbott Laboratories | Methods for the early detection of lung cancer |
| US9753037B2 (en) | 2013-03-15 | 2017-09-05 | Rush University Medical Center | Biomarker panel for detecting lung cancer |
| US20150072890A1 (en) * | 2013-09-11 | 2015-03-12 | 20/20 Gene Systems, Inc. | Methods and compositions for aiding in the detection of lung cancer |
| US20160060329A1 (en) * | 2014-07-28 | 2016-03-03 | Donald SIN | Compositions and methods for the diagnosis and prognosis of lung cancer |
| CA3198282A1 (en) * | 2015-06-26 | 2016-12-29 | Biomark Cancer Systems Inc. | Method of detecting lung cancer |
| EP3427051B1 (en) | 2016-03-08 | 2021-06-16 | Magarray, Inc. | Protein and autoantibody biomarkers for the diagnosis and treatment of lung cancer |
| CN105717146B (zh) * | 2016-03-29 | 2018-11-09 | 复旦大学附属中山医院 | 一种基于ct影像及生物标志物谱针对中国城市人口高危人群的肺癌风险预测试剂盒 |
| CN109478231A (zh) | 2016-04-01 | 2019-03-15 | 20/20基因系统股份有限公司 | 帮助区别良性和恶性放射线照相明显肺结节的方法和组合物 |
| EP3361256A1 (en) | 2017-02-08 | 2018-08-15 | Fundación para la Investigación Médica Aplicada | In vitro method for the diagnosis of lung cancer |
| CN110291397A (zh) | 2017-02-09 | 2019-09-27 | 得克萨斯大学体系董事会 | 肺癌的检测和治疗方法 |
| IL319255A (en) | 2017-08-07 | 2025-04-01 | Univ Johns Hopkins | Methods and materials for cancer assessment and treatment |
| KR20230080442A (ko) | 2020-10-02 | 2023-06-07 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 폐암의 검출 및 치료를 위한 방법 |
| WO2024107923A1 (en) | 2022-11-17 | 2024-05-23 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of lung cancer |
| TR2022022101A2 (tr) | 2022-12-31 | 2023-04-24 | Atatuerk Ueniversitesi Fikri Muelkiyet Haklari Koordinatoerluegue Doener Sermaye Isletmesi | Nemlendi̇ri̇ci̇ modelaj örtüsü |
| EP4721103A2 (en) | 2023-05-31 | 2026-04-08 | Board of Regents, The University of Texas System | Methods for the detection and treatment of lung cancer |
| WO2025064345A2 (en) | 2023-09-22 | 2025-03-27 | Board Of Regents, The University Of Texas System | Methods for the detection and treatment of lung cancer |
-
2018
- 2018-02-09 CN CN201880010925.0A patent/CN110291397A/zh active Pending
- 2018-02-09 CA CA3053116A patent/CA3053116A1/en active Pending
- 2018-02-09 EP EP24204031.9A patent/EP4528741A3/en not_active Withdrawn
- 2018-02-09 EP EP18752036.6A patent/EP3580560B1/en active Active
- 2018-02-09 KR KR1020247002923A patent/KR102827354B1/ko active Active
- 2018-02-09 KR KR1020197026040A patent/KR102630885B1/ko active Active
- 2018-02-09 ES ES18752036T patent/ES2995959T3/es active Active
- 2018-02-09 CN CN202311117176.0A patent/CN117368475A/zh active Pending
- 2018-02-09 US US16/484,177 patent/US12504430B2/en active Active
- 2018-02-09 WO PCT/US2018/017704 patent/WO2018148600A1/en not_active Ceased
- 2018-02-09 JP JP2019542716A patent/JP7311417B2/ja active Active
-
2023
- 2023-03-28 US US18/191,506 patent/US12405274B2/en active Active
-
2025
- 2025-11-10 US US19/384,269 patent/US20260063638A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3580560A1 (en) | 2019-12-18 |
| CN117368475A (zh) | 2024-01-09 |
| WO2018148600A1 (en) | 2018-08-16 |
| EP4528741A3 (en) | 2025-04-09 |
| KR20240015172A (ko) | 2024-02-02 |
| ES2995959T3 (en) | 2025-02-11 |
| US12504430B2 (en) | 2025-12-23 |
| CN110291397A (zh) | 2019-09-27 |
| EP4528741A2 (en) | 2025-03-26 |
| JP7311417B2 (ja) | 2023-07-19 |
| US20200025766A1 (en) | 2020-01-23 |
| KR102630885B1 (ko) | 2024-01-29 |
| KR20190116368A (ko) | 2019-10-14 |
| US20260063638A1 (en) | 2026-03-05 |
| US20230314436A1 (en) | 2023-10-05 |
| EP3580560A4 (en) | 2020-12-09 |
| JP2020510816A (ja) | 2020-04-09 |
| KR102827354B1 (ko) | 2025-06-30 |
| EP3580560B1 (en) | 2024-10-02 |
| US12405274B2 (en) | 2025-09-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20260063638A1 (en) | Methods for the detection and treatment of lung cancer | |
| Rho et al. | Protein and glycomic plasma markers for early detection of adenoma and colon cancer | |
| US20240159753A1 (en) | Methods for the detection and treatment of lung cancer | |
| US20230304993A1 (en) | Circulating tumor cell diagnostics for lung cancer | |
| Roe et al. | Mesothelin-related predictive and prognostic factors in malignant mesothelioma: a nested case–control study | |
| Marmor et al. | Biomarkers in lung cancer screening: a narrative review | |
| CN120188046A (zh) | 鉴定胰腺癌的方法 | |
| CN117831690A (zh) | 检测待测血样异常信号定量的计算机实施方法 | |
| WO2024107923A1 (en) | Methods for the detection and treatment of lung cancer | |
| WO2024249401A2 (en) | Methods for the detection and treatment of lung cancer | |
| WO2025064345A2 (en) | Methods for the detection and treatment of lung cancer | |
| Lu et al. | Auxiliary diagnosis of lung cancer on the basis of a serum protein biomarker panel | |
| Li et al. | Non-invasive diagnosis of pulmonary nodules by circulating tumor DNA methylation: A prospective multicenter study | |
| KR20240167655A (ko) | 면역 체크포인트 저해제 단제의 약리 작용과 비교한, 면역 체크포인트 저해제와 병용약으로서의 항암제의 조합의 상대적인 약리 작용의 평가 방법, 산출 방법, 평가 장치, 산출 장치, 평가 프로그램, 산출 프로그램, 기록 매체, 평가 시스템, 및 단말 장치 | |
| HK40105704A (zh) | 肺癌的检测和治疗方法 | |
| EP4692801A1 (en) | Multi-analyte blood tests tailored to seek, assess, and subtype pulmonary nodules | |
| WO2024250906A1 (en) | Methods of detecting lung cancer | |
| CN116529603A (zh) | 用于检测和治疗肺癌的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20230207 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241004 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250121 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 7TH ANNIV.) - STANDARD Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250131 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250131 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250131 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250521 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250521 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW Effective date: 20250530 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20250617 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250617 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250722 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250722 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251210 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20251229 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260213 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260213 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260323 |